Arcturus Therapeutics
Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare diseases, built on the STARR self-amplifying mRNA platform and the LUNAR lipid-mediated delivery system. Its pipeline includes ARCT-032 (LUNAR-CF, an mRNA therapeutic candidate for cystic fibrosis in Phase 2), ARCT-810 (LUNAR-OTC for ornithine transcarbamylase deficiency, Phase 2), KOSTAIVE (a self-amplifying COVID-19 vaccine approved in Japan), and Phase 1 influenza (ARCT-2138) and pandemic-influenza (ARCT-2304) programs. Headquartered in San Diego, the company beat Q2 2026 earnings estimates by $0.16 per share and traded up 21.9% on August 7, 2026 on above-average volume.
Company Info
Upcoming Milestones & Key Dates
Phase 2 updates for ARCT-032 (CF) and ARCT-810 (OTC) programs
Clinical Development Pipeline
ARCT-032 (LUNAR-CF)
Target: mRNA therapeutic encoding CFTR (LUNAR lipid delivery)ARCT-810 (LUNAR-OTC)
Target: mRNA therapeutic encoding ornithine transcarbamylaseKOSTAIVE
Target: Self-amplifying mRNA vaccine (STARR platform)ARCT-2138 (LUNAR-FLU)
Target: mRNA vaccineRecent News
No recent news updates available for this company.
Leadership Team
Joseph E. Payne
Founder, President and Chief Executive Officer
Dr. Padmanabh Chivukula
Founder, Chief Scientific Officer and Chief Operating Officer